Abstract

BackgroundAtherogenic dyslipoproteinemia is one of the most important risk factor for atherosclerotic changes development. Hypothyroidism is one of the most common causes of secondary dyslipidemias which results from reduced LDL clearance and therefore raised levels of LDL and apoB. Association between small dense LDL (sdLDL) presentation and thyroid status has been examinated using polyacrylamide gel electrophoresis for lipoprotein subfractions evaluation.Methods40 patients with diagnosed autoimmune hypothyroidism and 30 patients with autoimmune hyperthyroidism were treated with thyroxine replacement or thyreo-suppressive treatment. In both groups lipid profiles, LDL subractions, apolipoproteins (apoA1, apoB), apoA1/apoB ratio and atherogenic index of plazma (AIP) were examined before treatment and in state of euthyreosis.ResultsThyroxine replacement therapy significantly reduced levels of total cholesterol (TC), LDL, triglycerides (TG) and also decreased levels of sdLDL (8,55±11,671 vs 0,83±1,693mg/dl; p<0,001), apoB and AIP. For estimation of atherogenic lipoprotein profile existence an AIP evaluation seems to be better than apoB measurement because of the more evident relationship with sdLDL (r=0,538; p<0,01). Thyreo-suppressive therapy significantly increased levels of TC, LDL, TG and apoB. The sdLDL was not found in hyperthyroid patients.ConclusionsAtherogenic lipoprotein profile was present in 52.5% of hypothyroid subjects, which is higher prevalence than in normal, age-related population. Substitution treatment leads to an improvement of the lipid levels, TG, apoB, AIP and LDL subclasses. It significantly changed the presentation of sdLDL – we noticed shift to large, less atherogenic LDL particles. Significantly positive correlation between sdLDL and TAG; sdLDL and VLDL alerts to hypertriglyceridemia as a major cardiovascular risk factor.

Highlights

  • Atherogenic dyslipoproteinemia is one of the most important risk factor for atherosclerotic changes development

  • An inverse relationship between LDL particle size and level of plasminogen activator inhibitor-1, a factor associated with impaired fibrinolysis and atherosclerotic disease [15]. This makes from small dense LDL (sdLDL) strong atherogenic lipoprotein [5,7,16,17]

  • Patients with hypothyroidism were treated with levothyroxine

Read more

Summary

Introduction

Atherogenic dyslipoproteinemia is one of the most important risk factor for atherosclerotic changes development. SdLDLs have easier access to the subendothelial spaces in the arterial wall and exhibit enhanced binding to intimal proteoglycans [7,9,10] This increased risk of atherogenesis may be partially due to increased susceptibility to oxidation and glycation or to decreased clearance becouse of reduced affinity for the LDL receptor [7,11]. An inverse relationship between LDL particle size and level of plasminogen activator inhibitor-1, a factor associated with impaired fibrinolysis and atherosclerotic disease [15]. This makes from sdLDL strong atherogenic lipoprotein [5,7,16,17]. For these reasons the size determination of the LDL particles, is an important step in cardiovascular risk assessment, along with use of other certificated parameters

Objectives
Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.